- Home
- S vs LEGN Comparison
S vs LEGN Comparison
Compare S & LEGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | S | LEGN |
|---|---|---|
| Founded | 2013 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.0B | 5.9B |
| IPO Year | 2021 | 2020 |
Fundamental Metrics
Financial Performance| Metric | S | LEGN |
|---|---|---|
| Price | $17.78 | $27.08 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 31 | 12 |
| Target Price | $19.28 | ★ $61.33 |
| AVG Volume (30 Days) | ★ 6.0M | 2.1M |
| Earning Date | 05-27-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,001,278,000.00 | N/A |
| Revenue This Year | $22.84 | $42.68 |
| Revenue Next Year | $17.32 | $30.52 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 21.89 | N/A |
| 52 Week Low | $11.81 | $16.24 |
| 52 Week High | $21.40 | $45.30 |
Technical Indicators
Market Signals| Indicator | S | LEGN |
|---|---|---|
| Relative Strength Index (RSI) | 59.45 | 40.86 |
| Support Level | $14.09 | $24.94 |
| Resistance Level | $18.81 | $29.88 |
| Average True Range (ATR) | 0.93 | 1.35 |
| MACD | 0.27 | -0.48 |
| Stochastic Oscillator | 72.98 | 13.87 |
Price Performance
Historical ComparisonAbout S SentinelOne Inc.
SentinelOne is a cloud-based cybersecurity company specializing in endpoint protection. SentinelOne's primary offering is its Singularity platform that offers a single pane of glass for an enterprise to detect and respond to security threats attacking its IT infrastructure. The California-based firm was founded in 2013 and went public in 2021.
About LEGN Legend Biotech Corporation
Legend Biotech Corp is a clinical-stage biopharmaceutical company. It is engaged in the discovery and development of novel cell therapies for oncology and other indications. The firm's product candidate, LCAR-B38M/JNJ-4528, is a chimeric antigen receptor, or CAR, T cell therapy for the treatment of multiple myeloma. Geographically, the company generates a majority of its revenue from the United States of America. The company generates revenue from License and Collaboration revenue.